An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients with Advanced Refractory Solid Tumors

Trial Profile

An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients with Advanced Refractory Solid Tumors

Suspended
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs P 7170 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Piramal Enterprises
  • Most Recent Events

    • 02 Sep 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 03 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 Dec 2013 Planned End Date changed from 1 Mar 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top